SCHEMBL5381325

SCHEMBL5381325

CCSc1ccc(Cc2c(C)nc(C)[nH]c2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ GAA P10253 2/20 0.49
▸ KMT2A Q03164 5/20 0.45
▸ MEN1 O00255 4/20 0.45
▸ TSHR P16473 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.42
▸ THRB P10828 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ HTT P42858 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ AGTR1 P30556 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2610116 0.79 LMNA (0.64) LMNAHSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL5377375 0.77 SMN1; SMN2 (0.56) LMNAHSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL1895259 0.75 LMNA (0.74) LMNAHSD17B10SMN1; SMN2KMT2AMEN1
SCHEMBL2253149 0.74 SLC6A4 (0.41) SMN1; SMN2ALDH1A1NPSR1
SCHEMBL9235475 0.73 AR (0.59) LMNAHSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL4858658 0.71 SMN1; SMN2 (0.74) LMNAHSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL9486664 0.67 SLC6A4 (0.37) SMN1; SMN2ALDH1A1POLBHTT
SCHEMBL20828281 0.67 LMNA (0.74) LMNAHSD17B10SMN1; SMN2KMT2AMEN1
SCHEMBL11448905 0.67 LMNA (0.60) LMNAHSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL10857015 0.66 LMNA (0.70) LMNAHSD17B10SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7271153-B2 Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-09-18 — — US disclosed
US-20050049203-A1 Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-03-03 — — US disclosed
EP-1405859-A1 NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR Kissei Pharmaceutical Co., Ltd. (JP) 2004-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049203-A1 Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor GPR119, NPR3, SLC5A2 LMNA 2564/4885HSD17B10 305/4885SMN1; SMN2 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback